<DOC>
	<DOCNO>NCT01976741</DOCNO>
	<brief_summary>- This first study BAY1163877 give human . Impact study evaluate patient advance solid cancer show advanced clinical benefit treatment pan FGFR inhibitor . Patients ( comer ) receive study drug treatment dose-escalation scheme ( placebo group ) determine safety , tolerability maximum tolerate dose ( MTD ) BAY1163877 . The relative bioavailability liquid service formulation tablet determine . - After MTD define patient solid tumor ( comer ) , lung cancer ( lung adenocarcinoma &amp; squamous non-small cell lung cancer ) , head neck cancer bladder cancer enrol accord FGFR expression profile ( biomarker stratification ) . - The study also assess pharmacokinetics , biomarker status , pharmacodynamic parameter tumor response BAY1163877 . - BAY1163877 give twice daily oral application . Treatment stop tumor continue grow , side effect , patient tolerate , occur patient decides exit treatment .</brief_summary>
	<brief_title>Phase I Dose Escalation Pan-FGFR ( Fibroblast Growth Factor Receptor ) Inhibitor</brief_title>
	<detailed_description />
	<criteria>For dose escalation : Subjects type solid tumor ( comer ) eligible dose escalation dose expansion MTD Part 1 ; Subjects enrol dose expansion ( MTD expansion cohort `` comer '' ) stratify accord high fibroblast growth factor receptor ( FGFR ) expression level / FGFR mutation use archival fresh tumor biopsy material For expansion cohort : Subjects eligible Part 2 histological cytological confirm squamous nonsmall cell lung cancer ( sqNSCLC ) , lung adenocarcinoma , head neck cancer bladder cancer ( BC ) . All subject Part 2 stratify accord high FGFR expression level FGFR mutation use archival fresh tumor biopsy specimen . BC subject low overall FGFR expression level include activate FGFR3 ( FGFR tyrosine kinases3 ) mutation confirm Subjects must measurable disease ( Response evaluation criterion solid tumor ( RECIST 1.1 ) ) Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 2 Bone marrow , liver renal function assess adequate laboratory method conduct within 7 day prior start study Treatment Glomerular filtration rate ( GFR ) â‰¥ 30 mL/min/1.73 m2 accord modify diet renal disease ( MDRD ) abbreviate formula Previous treatment antiFGFR direct therapy ( e.g . receptor tyrosine kinase inhibitor FGFRspecific antibody ) Concomitant therapy discontinue switched different medication prior study entry know increase serum phosphate level permit within 4 week prior start study treatment ) Anticancer chemotherapy immunotherapy study within 5halflives prior start study treatment . Mitomycin C , nitrosoureas monoclonal antibody anticancer activity ( e.g . bevacizumab cetuximab etc . ) give within 6 week start receive study treatment within 6 week pretreatment biopsy biomarker ( pERK1/2 ) study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Dose escalation</keyword>
	<keyword>refractory , locally advanced metastatic solid tumor</keyword>
	<keyword>Bladder cancer</keyword>
	<keyword>squamous non-small cell lung cancer</keyword>
	<keyword>pan-FGFR inhibitor</keyword>
	<keyword>lung adenocarcinoma</keyword>
	<keyword>head neck cancer</keyword>
</DOC>